Skip to main content


Press Releases

February 28, 2018
GAITHERSBURG, Md., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26 million over 12 months for the continued supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the...


Maryland BioHealth Success Story 

Lynn R. Kieffer 
TEL 240-631-3391 

Robert Burrows 
TEL 240-631-3280